ImmunityBio (IBRX) Cost of Revenue (2025 - 2026)
ImmunityBio's (IBRX) quarterly Cost of Revenue came in at $238000.0 in Q1 2026, up 310.34% year-on-year from $58000.0 in Q1 2025, and down 37.7% on a QoQ basis from $382000.0 in Q4 2025.
ImmunityBio (IBRX) Cost of Revenue (2025 - 2026) Analysis & Trends
ImmunityBio (IBRX) has 2 years of Cost of Revenue data on file, last reported at $238000.0 in Q1 2026.
- On a quarterly basis, Cost of Revenue rose 310.34% year-over-year to $238000.0 in Q1 2026; TTM through Mar 2026 was $933000.0, a 1508.62% increase from a year earlier, with the FY2025 full-year figure at $753000.0, changed N/A from the prior year.
- Cost of Revenue for Q1 2026 stood at $238000.0, down from $382000.0 in the prior quarter.
- Over the last five years, Cost of Revenue for IBRX reached as high as $382000.0 in Q4 2025 and fell as low as $58000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | ImmunityBio | 7.22 Bn | 6.84 Bn | 43.97 Mn | 238,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 238,000.00 |
| Mar 31, 2026 | 238,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Dec 31, 2025 | 382,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Sep 30, 2025 | 177,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 136,000.00 |
| Mar 31, 2025 | 58,000.00 |
| Mar 31, 2025 | 58,000.00 |